PET-CT en el carcinoma anaplásico de tiroides y otros subtipos histológicos agresivos

  1. García-Talavera San Miguel, Paloma 1
  2. Díaz-González, Luis Gonzaga 1
  3. Gómez-Caminero, Felipe 1
  4. Riola Parada, Cristina 1
  5. Peñaherrera-Cepeda, Carolina 1
  6. Tamayo-Alonso, María Pilar 1
  1. 1 Servicio de Medicina Nuclear. Hospital Universitario de Salamanca
Revista:
Revista ORL

ISSN: 2444-7986,  2444-7986

Año de publicación: 2022

Volumen: 13

Número: 2

Páginas: 125-135

Tipo: Artículo

DOI: 10.14201/ORL.27382 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Otras publicaciones en: Revista ORL

Objetivos de desarrollo sostenible

Resumen

Introduction and objective: The aggressive histological subtypes of thyroid cancer are less common and have a worse prognosis than well –differentiated ones (DTC). The most important aggressive subtypes are Hürtle cell carcinoma (CHH), anaplasic and poorly differentiated carcinoma. In this review, we are going to evaluate the role of PET-CT, especially with 18F-FDG, in these aggressive histological lines, as well as in aggressive subtypes of DTC (tall cells, diffuse sclerosing…) and in radioiodine-refractory differentiated thyroid carcinoma. Synthesis: Although the main indication for 18F-FDG PET in thyroid cancer is suspected recurrence, in patients with DTC with elevated serum thyroglobulin and radioiodine-negative whole-body scan (WBS), this technique has increasing applications in DTC. Likewise, 18F-FDG PET is also an efficient diagnostic tool in the study of anaplastic carcinoma, poorly differentiated and other aggressive lines. It is recommended, in current clinical guidelines, as part of the initial staging in anaplastic, poorly differentiated, and invasive HCC. And it is increasingly used in other indications such as prognostic assessment, evaluation of treatment response, and even during the follow-up of high-risk patients. The use of other PET tracers, such as 68Ga-PSMA and 68Ga-DOTATATE have not clearly demonstrated their clinical benefit over 18F-FDG. They are usually limited to cases in which it is necessary to assess the density of somatostatin analogs and PSMA receptors prior to metabolic therapy.  Conclusions: 18F-FDG PET-CT is the most effective functional diagnostic technique in the study of poorly differentiated and aggressive thyroid neoplasms, since they show little or no avidity for radioiodine and however high affinity for 18F-FDG. The role of other PET tracers for the evaluation of these tumors is promising, although it still needs studies with a larger number of patients.

Referencias bibliográficas

  • Treglia G, Annunziata S, Muoio B, Salvatori M, Ceriani L, Giovanella L. The role of fluorine-18-fluorodeoxyglucose positron emission tomography in aggressive histological subtypes of thyroid cancer: an overview. Int J Endocrinol. 2013; 2013:856189.
  • Giovanella L, Ceriani L, De Palma D, Suriano S, Castellani M, Verburg FA. Relationship between serum thyroglobulin and 18F-FDG PET-CT in 131I-negative differentiated thyroid carcinomas. Head & Neck. 2012;34(5):626-31.
  • Caetano R, Bastos CR, de Oliveira IA, da Silva RM, Fortes CP, Pepe VL et al. Accuracy of PET and PET/CT in the detection of differentiated thyroid cancer recurrence with negative 131I whole body scan results: a meta-analysis. Head & Neck. 2016;38(2):316-27.
  • Muros MA, Mitjavila M, Estorch M, Lecumberri B, Navarro E. Utilidad de la FDG PET/CT en el cáncer de tiroides. Rev Esp Med Nucl Imagen Mol. 2016;35(3):186-192.
  • Grabellus F, Nagarajah J, Bockisch A, Schmid KW, Asheu SY. Glucose transporter 1 expression, tumour proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med. 2012;37(2):121-7.
  • Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K et al. Thyroid cancer: ESMO Clinical Practise guidelines form diagnosis, treatment and follow-up. Ann Oncol. 2019;30(12):1856-83.
  • Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133.
  • Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Straus HW. Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]-Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography Scanning. J Clin Endocrinol Metab. 2006;91(2):498-505.
  • Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA et al. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab. 2009;94(4):1310-6.
  • Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019. JAMA Oncol. 2020;6(9):1397-1404.
  • Haddad RI, Bischoff L, Bernet L, Blomain E, Busaidy NL, Dickson N et al. NCCN Clinical Practice Guidelines in Oncology: Thyroid carcinoma, version 1.2021 [Internet]. 2021 [citado 18 de julio de 2021]. Recuperado a partir de: https://www.nccn.org/guidelines/recently-published-guidelines
  • Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ Jr et al. 2021 American Thyroid Assiciation Guidelines form management of patients with anaplastic Thyroid carcinoma. Thyroid. 2021;31(3):337-86.
  • Poisson T, Deandreis D, Leboulleux S, Bidault F, Bonniaud G, Baillot S et al. 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37(12):2277-85.
  • Levy A, Leboulleux S, Lepoutre-Lussey C, Baudin E, Al Ghuzlan AA, Hartl D et al. [18F]-fluorodeoxyglucose positron emission tomography to assess response after radiation therapy in anaplastic thyroid cancer. Oral Oncol. 2015;51(4):370-5.
  • Kim HJ, Chang HS and Ryu YH. Prognostic role of pre-treatment [18F]-FDG PET/CT in patients with anaplastic thyroid cancer. Cancers. 2021;13(16):4228.
  • Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol. 2004;15(4):319-27.
  • Araz M, Çay?r D. 18F-Fluordeoxyglucose-positron emission tomography/computed tomography for other thyroid cancers: medullary, anaplastic, lymphoma and so forth. Mol Imaging Radionucl Ther. 2017;26(1):1-8.
  • Nascimento C, Borget I, Ghuzlan AA, Deandreis D, Hartl D, Lumbroso J, et al. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. Thyroid. 2015;25(4):437-44.
  • Diehl M, Graichen S, Menzel C, Lindhost E, Grünwald F. F-18 FDG PET in insular thyroid cancer. Clin Nucl Med. 2003;28(9):728-31.
  • Coca-Pelaz A, Rodrigo JP, Shah JP, Sanabria A, Ghuzlan AA, Silver CE et al. Hürthle cell carcinoma of the thyroid gland: systematic review and meta-analysis. Adv Ther. 2021. https://doi.org/10.1007/s12325-021-01876-7.
  • Lowe VJ, Mullan BP, Hay ID, McIver B, Kasperbauer JL. 18F-FDG PET of patients with Hürtle Cell Carcinoma. J Nucl Med. 2003;44(9):1402-6.
  • Pryma DA, Schöder H, Gönen M, Robbins RJ, Larson SM, Yeung HW. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. J Nucl Med. 2006;47(8):1260-6.
  • Plotkin M, Hautzel H, Krause BJ, Schmidt D, Larisch R, Mottaghy FM et al. Implication of 2-18-fluor-2-deoxyglucose positron emission tomography in the follow-up of Hürthle cell thyroid cancer. Thyroid. 2002;12(2):155-61.
  • Yang JH, Maciel RMB, Nakabashi CCD, Janovsky CCPS, Padovani RP, Macellaro D et al. Clinical utility of FDG PET/CT in the follow up of a large cohort of patients with high-risk differentiated thyroid carcinoma. Arch Endocrinol Metab. 2017;61(5):416-25.
  • Aller Pardo J. El paciente refractario a radioyodo. Terapia sistémica. En: Galofré J, editor. Cáncer de tiroides. Guía de consulta rápida. Majadahonda (Madrid): Ergon creación; 2017. p. 129-40. ISBN: 978-84-16732-41-8.
  • Schlumberger M, Brose M, Elisei R, Leboulleux S, Luster M, Pitoia F et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014;2(5):356-8.
  • Kolodziej M, Saracyn M, Lubas A, Brodowska-Kania D, Mazurek A, Dziuk M et al. Evaluation of the usefulness of positron emission tomography with [18F]-fluorodeoxylglucose performed to detect non-radioiodine avid recurrence and/or metastasis of differentiated thyroid cancer. A preliminary study. Nucl Med Rev Cent East Eur. 2021;24(2):63-9.
  • Haslerud T, Brauckhoff K, Reisæter L, Küfner Lein R, Heinecke A, Varhaug JE et al. F18 -FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis. Acta Radiol. 2016:57(10):1193-200.
  • Deandreis D, Al Ghuzlan A, Leboulleux S, Lacroix L, Garsi P, Talbot M et al. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer. 2011;18(1):159-69.
  • Lawhn-Heath C, Yom SS, Liu C, Villanueva-Meyer JE, Aslam M, Smith R et al. Gallium-68 prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study. EJNMMI Research. 2020;10(1):128.
  • Bychkov A, Vutrapongwatana U, Tepmongkol S, Keelawat S. PSMA expression by microvasculature of thyroid tumors - potential implications for PSMA theranostics. Sci Rep. 2017;7(1):5202.
  • Lengana T, Lawal IO, Mokoala K, Vorster M, Sathekge MM. 68Ga-PSMA: a one-stop shop in radioactive iodine refractory thyroid cancer? Nucl Med Mol Imaging. 2019;53(6):442–5.
  • Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, et al. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J Nucl Med. 2018;59(1):66–74.
  • Roll W, Riemann B, Schäfers M, Stegger L, Vrachimis A. 177Lu-DOTATATE therapy in radioiodine-refractary differentiated thyroid cancer: a single center experience. Clin Nucl Med. 2018;43(10): e346-51.
  • Maghsoomi Z, Emami Z, Malboosbaf, Malek M, Khamseh ME. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review. BMC cancer. 2021;21(1):579.
  • Binse I, Poeppel TD, Ruhlmann M, Ezziddin S, Görges R, Sabet A, et al. Ga-DOTATOC PET/CT in patients with iodine and 18F-FDG-negative differentiated thyroid carcinoma and elevated serum thyroglobulim. J Nucl Med. 2016;57(10):1512-7.
Fuente de los datos: Dialnet